The drug development consultancy announces the opening of a Paris office to serve its increasing French customer base and in continuation of its strategic global expansion.
This is NDA’s fifth European location, having offices in Stockholm, London, Munich and Zürich. The Paris office will complement the existing capabilities in other European offices to support more frequent client interactions and strategic regulatory support on site.
“NDA has had close relationships with many of the drug developing companies in France and French speaking Europe for many years. I am therefore delighted to finally be able to announce the opening of our new offices in one of the most prominent capitals of the EU,” says Johan Strömquist, CEO of NDA Group. “NDA having a presence in Paris is important to our French clients and other drug development companies in the area. It gives faster access to our great pool of expertise and makes it even easier to communicate across the borders. Ultimately I believe this will help French companies develop their products even better than today and reach the patients they’re targeting even faster.”
“We are so excited about our new office. The Paris office provides a critical location in Europe to service a range of biotech and pharmaceutical companies within France and environs that are easily accessed from this international hub. We will begin with direct business development and outreach to make our global services and our amazing people known to a broader client base,” says Dr. Laurie Smaldone Alsup, MD, CSO and COO of NDA Group.